ArticleScience translational medicine2021
Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Predicting Immunotherapy Efficacy with Machine Learning in Gastrointestinal Cancers: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Characterization of a Phage Display-Selected scFv Against Neuropilin 1 (NRP1) Isolated from a Naïve Human Library.Molecular biotechnology · 2026Article
- Article
- LncRNA NEAT1 promotes immunosuppression in gastric cancer under endoplasmic reticulum stress by maintaining the MMolecular cancer · 2026Article
- FANCD2 knockdown suppresses malignant phenotypes and is associated with caspase/PARP-mediated apoptosis in NCI-H2052 pleural mesothelioma cells.Frontiers in genetics · 2026Article
- Crosstalk between NRP1 and autophagy in the tumor microenvironment: from molecular mechanisms to therapeutic targeting.Frontiers in immunology · 2026Review
- Characterizing the Head and Neck Cancer Microenvironment: Implications for Immunotherapy and Prognosis.Advances in experimental medicine and biology · 2026Review
- IGF2BP1 fosters an immunosuppressive tumor microenvironment in high-risk neuroblastoma, contributing to their resistance to immunotherapy.Oncoimmunology · 2025Article
- MEF2D-expressing cancer precursors reprogram tissue-resident macrophages to support liver tumorigenesis.Nature cancer · 2025Article
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs.Chemical reviews · 2025Review
- Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade.Molecular oncology · 2025Article
- Immunotherapeutic strategies in head and neck cancer: challenges and opportunities.The Journal of clinical investigation · 2025Review
- Harnessing the biology of regulatory T cells to treat disease.Nature reviews. Drug discovery · 2025Review
- Engineering mRNA CAR-T Cells for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- KDM3A Ablation Activates Endogenous Retrovirus Expression to Stimulate Antitumor Immunity in Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Regulatory T Cell Insufficiency in Autoimmune Diabetes Is Driven by Selective Loss of Neuropilin-1 on Intraislet Regulatory T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Selective targeting or reprogramming of intra-tumoral Tregs.Medical oncology (Northwood, London, England) · 2024Review
- The Nervous System Development Regulator Neuropilin-1 as a Potential Prognostic Marker and Therapeutic Target in Brain Cancer.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 5 institutions in 1 country.
Christopher A ChuckranDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-0364-806X
Anthony R CilloDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-3213-3129
Jessica MoskovitzTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.ORCID 0000-0003-2360-6411
Abigail Overacre-DelgoffeDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-4027-3487
Ashwin S SomasundaramTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.ORCID 0000-0003-3167-406X
Feng ShanDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-3660-8475
Grant C MagnonDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Sheryl R KunningDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0001-7529-040X
Irina AbecassisTumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
Amer H ZureikatDepartment of Surgery, Division of Surgical Oncology, UPMC Hillman Cancer Center and UPMC Pancreatic Cancer Program, Pittsburgh, PA 15213, USA.ORCID 0000-0002-7800-5464
James LuketichDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-6578-6169
Arjun PennathurDepartment of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0001-7937-7991
John SembratPittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0003-4108-803X
Mauricio RojasPittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA.ORCID 0000-0001-7340-4784
Daniel T MerrickDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-3618-6121
Sarah E TaylorDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Brian OrrDepartment Obstetrics and Gynecology, Gynecologic Oncology Division, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0003-0158-1575
Francesmary ModugnoDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-0637-1534
Ron BuckanovichDivision of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-5665-9790
Robert E SchoenDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0001-7153-2766
Seungwon KimDepartment of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-1379-2601
Umamaheswar DuvvuriDepartment of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0003-1968-3756
Herbert ZehHarold C. Simmons Comprehensive Cancer Center, UT Southwestern, Dallas, TX 75390, USA.ORCID 0000-0003-2017-1934
Robert EdwardsDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
John M KirkwoodDepartments of Medicine, Dermatology, and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-3570-4476
Lan CoffmanDivision of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-3753-1652
Robert L FerrisDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Tullia C BrunoDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-6433-0207
Dario A A VignaliDepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.ORCID 0000-0002-2771-5992
University of Pittsburgh · USUPMC Hillman Cancer Center · USMedical University of South Carolina · USSouthwestern Medical Center · USUniversity of Colorado Anschutz Medical Campus · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MUniversity of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3MWILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6MSynergies among inhibitory receptors in tolerance, cancer & antiviral immunityP01AI108545 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Dario AA Vignali · 2015 to 2026
$30.8MTherapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B., ODUNSI, KUNLE · 2013 to 2025
$19.6MRefinement and Discovery of Nuclear Matrix Protein Markers for Colorectal CancerU01CA152753 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KINZLER, KENNETH W., SCHOEN, ROBERT E. · 2010 to 2021
$6.8MPostdoctoral Training in Head and Neck OncologyT32CA060397 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZEVALLOS, JOSE P. · 1994 to 2024
$2.7MInterleukin-35 and the tumor microenvironmentR01CA203689 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VIGNALI, DARIO AA · 2016 to 2020
$1.9MNeuropilin-1 Stabilizes Human Tregs in Cancer Patients Thereby Enhancing Suppressive FunctionF31CA243168 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHUCKRAN, CHRISTOPHER · 2019 to 2020
$91kNCATS NIH HHS UL1 TR001857NCI NIH HHS F31 CA243168NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS P50 CA121973NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA203689NCI NIH HHS T32 CA060397NCI NIH HHS U01 CA152753NIAID NIH HHS P01 AI108545
Abstract
Despite the success of immune checkpoint blockade therapy, few strategies sufficiently overcome immunosuppression within the tumor microenvironment (TME). Targeting regulatory T cells (T
Indexed as
Head and Neck NeoplasmsNeuropilin-1AnimalsHumansImmunotherapyMicePrevalenceT-Lymphocytes, RegulatoryTumor MicroenvironmentNeuropilin-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.